PP97 Insulin Analogs In Type 1 Diabetes: Why Are There Barriers To Its Access In The Brazilian Unified Health System?
Luiza Nascimento-Costa, Rosangela Caetano, Ione Ayala Gualandi Oliveira, Ione Oliveira · 2025
Read PP97 Insulin Analogs In Type 1 Diabetes: Why Are There Barriers To Its Access In The Brazilian Unified Health System? by Luiza Nascimento-Costa, Rosangela Caetano, Ione Ayala Gualandi Oliveira, Ione Oliveira (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768597.txt.
Description
Luiza Nascimento-Costa and co-authors ask why approved insulin drugs fail to reach Brazilian patients in a 2025 study. Modern insulin analogs entered the public health system on paper in 2017 and 2019. In practice, supply lagged badly, and patients kept suing for access. The team traced the gap using committee records, ministry purchases, and dispensing data from 2011 to 2022.
Rules say supply should begin within 180 days of approval. For short-acting analogs, the first dispensing came after 575 days, more than a year late. Long-acting versions also missed the mark. The study names the delay between decree and delivery as the core barrier. It shows how a favorable decision alone does not put medicine in patients' hands.
Catalog record
| CREATOR | Luiza Nascimento-Costa, Rosangela Caetano, Ione Ayala Gualandi Oliveira, Ione Oliveira |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |